Risk-benefit assessment of therapies for Mycobacterium avium complex infections.

This publication has 47 references indexed in Scilit:

• Initial (6-Month) Results of Three-Times-Weekly Azithromycin in Treatment Regimens for Mycobacterium avium Complex Lung Disease in Human Immunodeficiency Virus-Negative Patients
  The Journal of Infectious Diseases, 1998
• A Randomized Evaluation of Ethambutol for Prevention of Relapse and Drug Resistance during Treatment ofMycobacterium aviumComplex Bacteremia with Clarithromycin‐Based Combination Therapy
  The Journal of Infectious Diseases, 1997
• Reduced Serum Levels Of Clarithromycin In Patients Treated With Multi-Drug Regimens Including Rifampin Or Rifabutin For Mycobacterium Avium-M. Intracellulare Infection
  The Journal of Infectious Diseases, 1995
• The Impact Of Mycobacterium AviumComplex Bacteremia And Its Treatment On Survival Of Aids Patients-A Prospective Study
  The Journal of Infectious Diseases, 1994
• Uveitis and Pseudojaundice During a Regimen of Clarithromycin, Rifabutin, and Ethambutol
  New England Journal of Medicine, 1994
• The new macrolides. Azithromycin and clarithromycin.
  1994
• Intracellular accumulation of azithromycin by cultured human fibroblasts
  Antimicrobial Agents and Chemotherapy, 1990
• Dose-limiting toxicity of rifabutin in AIDS-related complex
  AIDS, 1990
• Treatment of Disease Due to Mycobacterium intracellulare
  Clinical Infectious Diseases, 1981
• Treatment of pulmonary infections caused by mycobacteria of the Mycobacterium avium-intracellulare complex.
  Thorax, 1981